|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
|
|
2
|
Wachtel MS, Nelius T, Haynes AL, Dahlbeck
S and de Riese W: PSA screening and deaths from prostate cancer
after diagnosis - a population bases analysis. Prostate.
73:1365–1369. 2013.
|
|
3
|
Moyer VA; U.S. Preventive Services Task
Force. Screening for prostate cancer: U.S. Preventive Services Task
Force recommendation statement. Ann Intern Med. 157:120–134.
2012.
|
|
4
|
Sandhu GS, Nepple KG, Tanagho YS and
Andriole GL: Prostate cancer chemoprevention. Semin Oncol.
40:276–285. 2013.
|
|
5
|
Klein EA, Thompson IM Jr, Tangen CM, et
al: Vitamin E and the risk of prostate cancer: the Selenium and
Vitamin E Cancer Prevention Trial (SELECT). JAMA. 306:1549–1556.
2011.
|
|
6
|
Schwartz GG: Vitamin D, sunlight, and the
epidemiology of prostate cancer. Anticancer Agents Med Chem.
13:45–57. 2013.
|
|
7
|
No authors listed. The effect of vitamin E
and beta carotene on the incidence of lung cancer and other cancers
in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer
Prevention Study Group. N Engl J Med. 330:1029–1035. 1994.
|
|
8
|
Raghow S, Hooshdaran MZ, Katiyar S and
Steiner MS: Toremifene prevents prostate cancer in the transgenic
adenocarcinoma of mouse prostate model. Cancer Res. 62:1370–1376.
2002.
|
|
9
|
Roberts RO, Jacobson DJ, Girman CJ, et al:
A population-based study of daily nonsteroidal anti-inflammatory
drug use and prostate cancer. Mayo Clin Proc. 77:219–225. 2002.
|
|
10
|
Irani J, Ravery V, Pariente JL, et al:
Effect of nonsteroidal anti-inflammatory agents and finasteride on
prostate cancer risk. J Urol. 168:1985–1988. 2002.
|
|
11
|
Bonovas S, Filioussi K and Sitaras NM:
Statin use and the risk of prostate cancer: A metaanalysis of 6
randomized clinical trials and 13 observational studies. Int J
Cancer. 123:899–904. 2008.
|
|
12
|
Thomas JA II, Gerber L, Moreira DM, et al:
Prostate cancer risk in men with prostate and breast cancer family
history: results from the REDUCE study (R1). J Intern Med.
272:85–92. 2012.
|
|
13
|
Coffey DS and Walsh PC: Clinical and
experimental studies of benign prostatic hyperplasia. Urol Clin
North Am. 17:461–475. 1990.
|
|
14
|
Steers WD: 5alpha-reductase activity in
the prostate. Urology. 58:17–24. 2001.
|
|
15
|
Platz EA and Giovannucci E: The
epidemiology of sex steroid hormones and their signaling and
metabolic pathways in the etiology of prostate cancer. J Steroid
Biochem Mol Biol. 92:237–253. 2004.
|
|
16
|
Thompson IM, Goodman PJ, Tangen CM, et al:
The influence of finasteride on the development of prostate cancer.
N Engl J Med. 349:215–224. 2003.
|
|
17
|
Andriole G, Bostwick D, Brawley O, et al:
Chemoprevention of prostate cancer in men at high risk: rationale
and design of the reduction by dutasteride of prostate cancer
events (REDUCE) trial. J Urol. 172(4 Pt 1): 1314–1317. 2004.
|
|
18
|
Andriole GL, Bostwick DG, Brawley OW, et
al: Effect of dutasteride on the risk of prostate cancer. N Engl J
Med. 362:1192–1202. 2010.
|
|
19
|
Redman MW, Tangen CM, Goodman PJ, et al:
Finasteride does not increase the risk of high-grade prostate
cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila).
1:174–181. 2008.
|
|
20
|
Roehrborn CG, Boyle P, Bergner D, et al:
Serum prostate-specific antigen and prostate volume predict
long-term changes in symptoms and flow rate: results of a
four-year, randomized trial comparing finasteride versus placebo.
PLESS Study Group Urology. 54:662–669. 1999.
|
|
21
|
Pinsky P, Parnes H and Ford L: Estimating
rates of true high-grade disease in the prostate cancer prevention
trial. Cancer Prev Res (Phila). 1:182–186. 2008.
|
|
22
|
Cohen YC, Liu KS, Heyden NL, et al:
Detection bias due to the effect of finasteride on prostate volume:
a modeling approach for analysis of the Prostate Cancer Prevention
Trial. J Natl Cancer Inst. 99:1366–1374. 2007.
|
|
23
|
Kaplan SA, Roehrborn CG, Meehan AG, et al:
PCPT: Evidence that finasteride reduces risk of most frequently
detected intermediate- and high-grade (Gleason score 6 and 7)
cancer. Urology. 73:935–939. 2009.
|
|
24
|
Borden LS Jr, Wright JL, Kim J,
Latchamsetty K and Porter CR: An abnormal digital rectal
examination is an independent predictor of Gleason > or =7
prostate cancer in men undergoing initial prostate biopsy: a
prospective study of 790 men. BJU Int. 99:559–563. 2007.
|
|
25
|
Choo R, Danjoux C, Morton G, et al: How
much does Gleason grade of follow-up biopsy differ from that of
initial biopsy in untreated, Gleason score 4–7, clinically
localized prostate cancer? Prostate. 67:1614–1620. 2007.
|
|
26
|
Pinsky PF, Black A, Grubb R, et al:
Projecting prostate cancer mortality in the PCPT and REDUCE
chemoprevention trials. Cancer. 119:593–601. 2013.
|
|
27
|
Thompson IM Jr, Goodman PJ, Tangen CM, et
al: Long-term survival of participants in the prostate cancer
prevention trial. N Engl J Med. 369:603–610. 2013.
|
|
28
|
Grubb RL, Andriole GL, Somerville MC, et
al: The REDUCE Follow-Up Study: low rate of new prostate cancer
diagnoses observed during a 2-year, observational, followup study
of men who participated in the REDUCE trial. J Urol. 189:871–877.
2013.
|
|
29
|
Theoret MR, Ning YM, Zhang JJ, et al: The
risks and benefits of 5α-reductase inhibitors for prostate-cancer
prevention. N Engl J Med. 365:97–99. 2011.
|
|
30
|
Fleshner NE, Lucia MS, Egerdie B, et al:
Dutasteride in localised prostate cancer management: the REDEEM
randomised, double-blind, placebo-controlled trial. Lancet.
379:1103–1111. 2012.
|
|
31
|
Kattan MW, Earnshaw SR, McDade CL, Black
LK and Andriole GL: Cost effectiveness of chemoprevention for
prostate cancer with dutasteride in a high-risk population based on
results from the REDUCE clinical trial. Appl Health Econ Health
Policy. 9:305–315. 2011.
|
|
32
|
Svatek RS, Lee JJ, Roehrborn CG, Lippman
SM and Lotan Y: Cost-effectiveness of prostate cancer
chemoprevention: a quality of life-years analysis. Cancer.
112:1058–1065. 2008.
|
